Prelude Therapeutics (PRLD) investor relations material

Executive summary

• Focused on precision oncology, advancing a pipeline of novel cancer medicines targeting high unmet needs, with key programs in KAT6A degraders and JAK2V617F inhibitors for breast cancer and myeloproliferative neoplasms, respectively.

• Entered an exclusive option agreement with Incyte for the JAK2V617F program, potentially worth up to $910 million in milestone and upfront payments.

• Restructured collaboration with AbCellera, granting non-exclusive licenses for select degrader antibody conjugates and receiving upfront payments.

• Presented differentiated preclinical data for KAT6A degrader and mCALR-targeted DACs at major scientific meetings.

• Appointed a new Chief Medical Officer in April 2026.

Financial highlights

• Revenue for Q2 2026 was $5.7 million, and $10.3 million for the first half of 2026, all from the Incyte agreement.

• Net loss for Q2 2026 was $13.9 million ($0.14 per share), a significant improvement from $31.2 million ($0.41 per share) in Q2 2025; six-month net loss was $24.3 million, down from $63.3 million year-over-year.

• Research and development expenses decreased to $16.1 million in Q2 2026 from $25.8 million in Q2 2025, reflecting program reprioritization and workforce reduction.

• Cash, cash equivalents, restricted cash, and marketable securities totaled $155.2 million as of June 30, 2026, providing runway into Q2 2028.

• G&A expenses fell to $5.0 million from $6.4 million year-over-year, reflecting lower stock-based compensation and employee costs.

Outlook and guidance

• Funds on hand expected to cover operating and capital expenditures for at least the next twelve months and into Q2 2028.

• Anticipates continued operating losses as product candidates advance through clinical development.

• Plans to initiate Phase 1 study of KAT6A degrader PRT13722 in HR+ breast cancer in Q4 2026, pending IND clearance, and continue enrolling JAK2V617F inhibitor PRT12396 in Phase 1.